江苏诺泰澳赛诺生物制药股份有限公司独立董事 关于公司续聘会计师事务所的事前认可意见 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上海证券交易所 科创板股票上市规则》、《上市公司独立董事规则》等法律、法规及规范性文件及《公 司章程》的相关规定，我们作为江苏诺泰澳赛诺生物制药股份有限公司（以下简称 "公司"）的独立董事，本着勤勉尽责的态度，依据客观公正的原则，对公司续聘会 计师事务所进行了认真的审查，现发表如下事前认可意见： 公司 2022 年度聘请了中天运会计师事务所（特殊普通合伙）担任本公司财务审 计机构，在对公司各专项审计和财务报表审计过程中，该所能够按照国家有关规定 及注册会计师职业规范的要求开展审计工作，独立、客观的发表审计意见，建议继 续聘任中天运会计师事务所（特殊普通合伙）担任本公司 2023 年度审计机构及内部 控制审计机构，同意公司将该议案提交第三届董事会第十三次会议审议。 江苏诺泰澳赛诺生物制药股份有限公司 独立董事：徐强国、高集馥、曲峰、胡文言 2023 年 8 月 21 日 ...

经核查，我们认为：中天运会计师事务所（特殊普通合伙）具备从事证券、 期货相关业务的资格，具有丰富的上市公司审计经验和素质优良的执业队伍，可 以满足公司 2023 年度审计业务的要求。本次续聘会计师事务所事项已经公司全 体独立董事事前认可、董事会审计委员会审议通过，履行了必要的决策程序，符 合《公司法》、《国有企业、上市公司选聘会计师事务所管理办法》和《公司章程》 等相关规定，不存在损害公司和股东利益的行为。因此，我们一致同意聘任中天 运会计师事务所（特殊普通合伙）为公司 2023 年度会计师事务所，聘期一年， 并提交公司股东大会审议。 江苏诺泰澳赛诺生物制药股份有限公司 独立董事：徐强国、高集馥、曲峰、胡文言 2023 年 8 月 28 日 一、《关于公司<2023 年半年度募集资金存放与实际使用情况的专项报告> 的议案》的独立意见 经核查，我们认为：报告期内，公司严格按照《上海证券交易所科创板股票 上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等法律法规和公司《募集资金管理办法》等文件的规定管理和使用募集资金，并 及时进行信息披露，不存在募集资金存放和使用重大违法违规的情形。 ...

证券代码：688076 证券简称：诺泰生物 公告编号：2023-063 江苏诺泰澳赛诺生物制药股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 2023 年 7 月 25 日，江苏诺泰澳赛诺生物制药股份有限公司（以下简称"诺 泰生物"或"公司"）于上海证券交易网站披露了《关于股东存续分立完成的公 告》（公告编号：2023-060）, 公司股东建德市五星生物科技有限公司（以下简 称"五星生物"）完成存续分立，五星生物所持 10,314,700 股公司股份已全部过 户给分立公司建德市星联企业管理有限公司（以下简称"星联管理"）。 截至本公告披露之日，公司股东星联管理持有公司股份 10,314,700 股，占 公司总股本的 4.84%；建德市上将企业管理有限公司（以下简称"上将管理"）持 有公司股份 8,809,794 股，占公司总股本的 4.13%；股东潘婕持有公司股份 594,141 股，占公司总股本的 0.28%。星联管理、上将管理、潘婕作为 ...

证券代码：688076 证券简称：诺泰生物 公告编号：2023-042 江苏诺泰澳赛诺生物制药股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 06 月 01 日(星期四) 下午 14:00-15:00 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 05 月 25 日(星期四) 至 05 月 31 日(星期三)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@sinopep.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 22 日发布公司 2022 年度报告及 2023 年第一季度报告，为便于广大投资者 ...

Dividend Distribution - The company plans to distribute a cash dividend of RMB 2.00 per 10 shares to all shareholders, totaling RMB 42,636,760.00 based on a total share capital of 213,183,800 shares as of March 31, 2023[5]. - The company has a total share capital of 213,183,800 shares as of March 31, 2023, which is the basis for the proposed dividend distribution[5]. - The company has not engaged in any capital increase through bonus shares or conversion of capital reserves into share capital for the 2022 fiscal year[5]. Operational Risks and Governance - The company has not reported any profits since its listing and continues to face operational risks as detailed in the report[18]. - The company has implemented a series of governance improvements, including revisions to various internal management systems to enhance operational compliance and protect shareholder rights[26]. - The company has outlined various risk factors that may impact its future operations, emphasizing the uncertainties in its forward-looking statements[11]. Investor Relations and Communication - The company has established effective communication channels with investors, including email, on-site research, and official social media platforms, to disseminate strategic and operational updates[26]. - The company has established a structured approach to investor relations management, with designated personnel responsible for coordinating communication and addressing investor inquiries[30]. - The company commits to maintaining strict compliance with information disclosure obligations to ensure transparency and accuracy in reporting[26]. Share Transfer and Lock-up Regulations - Shareholders are restricted from transferring shares for one year from the date of listing on the Shanghai Stock Exchange[40]. - The company commits to not transferring or managing its shares directly or indirectly for 12 months post-IPO and for 6 months after any executive's departure[39]. - Any shareholder's transfer of pre-IPO shares is limited to 25% of their total pre-IPO shares each year for four years post-lockup expiration[39]. - If the closing price falls below the issue price for 20 consecutive trading days, the lock-up period will be extended by 6 months[42]. - The lock-up period for shareholders will automatically extend if the stock price remains below the issue price at the end of the 6-month period post-IPO[43]. - The company emphasizes strict adherence to share lock-up and reduction commitments to ensure compliance with regulatory requirements[45]. Stock Price Stabilization Measures - The company commits to stabilize its stock price if it falls below the audited net asset value per share for 20 consecutive trading days within three years post-IPO[46]. - Stock repurchase will be the first option for stabilizing the stock price, with a limit of 10% of total shares and funding not exceeding 20% of the previous year's net profit attributable to shareholders[46]. - If the stock repurchase plan is not approved or cannot be implemented, the actual controller and major shareholders will increase their holdings as the second option[46]. - The company must hold a board meeting within 10 days to decide on the stock repurchase if the stabilization conditions are met[46]. - The stock repurchase must be completed within three months after the shareholders' meeting approval[46]. - The company will only be obligated to initiate stock price stabilization measures once per fiscal year[46]. - If the stock price exceeds the audited net asset value for three consecutive trading days during the stabilization period, the obligation is considered fulfilled for that year[46]. - The company will ensure that any stock repurchase does not lead to non-compliance with legal listing requirements[46]. - The stabilization measures will be suspended if the stock price rises above the audited net asset value before the implementation of the plan[46]. Financial Performance and Investments - The total amount of funds raised for the Hangzhou Aoxin Pharmaceutical Intermediate Construction Project is CNY 150 million, with a cumulative investment of CNY 119.62 million, achieving a progress rate of 79.75%[110]. - The Peptide Raw Material Drug Product Technical Transformation Project has a total fundraising commitment of CNY 250 million, with a cumulative investment of CNY 18.37 million, resulting in a progress rate of 7.35%[111]. - The total amount of funds raised for the Peptide Drug and High-end Preparation R&D Center Project is CNY 100 million, with a cumulative investment of CNY 32.42 million, achieving a progress rate of 32.42%[111]. - The company has achieved benefits of CNY 47.22 million from the investment projects[110]. - The company has a remaining balance of CNY 31.25 million from the fundraising projects, with reasons for the surplus detailed in the report[110]. Environmental Compliance - The company has implemented measures to ensure that waste gas and wastewater meet environmental standards before discharge, with zero emissions for solid waste[160]. - The Lianyungang production base has received multiple environmental approvals from regulatory authorities, ensuring compliance with environmental regulations[160]. - The company’s wastewater treatment facilities have been approved, with the latest permit renewal for the JianDe production base on December 2, 2022[160]. - The company has established a comprehensive environmental management system, including noise reduction measures and the use of green plants for sound absorption[162]. - The company is focused on maintaining zero discharge of solid waste, reflecting its commitment to environmental sustainability[160]. Shareholder Structure and Changes - The total number of common shareholders as of the end of the reporting period is 10,938, an increase from 10,609 at the end of the previous month[151]. - The top ten shareholders hold a total of 66,000,000 shares, representing 30.94% of the total shares[151]. - The largest shareholder, Lianyungang Nuotai Investment Management Partnership, holds 20,000,000 shares, accounting for 9.38% of the total shares[151]. - The company has not reported any significant changes in shareholder structure or asset and liability structure during the reporting period[125]. - The company has not reported any changes in the number of shares held by the top shareholders during the reporting period[155]. Financial Position - Total assets increased to ¥2,522,299,186.67, up from ¥2,126,905,940.12, representing a growth of approximately 18.6% year-over-year[198]. - Non-current assets totaled ¥1,469,829,602.50, compared to ¥1,022,805,046.06, marking a significant increase of about 44%[198]. - Short-term borrowings rose to ¥318,725,147.08 from ¥77,274,866.38, indicating a substantial increase of approximately 312%[198]. - Current liabilities totaled ¥551,323,149.93, up from ¥275,395,497.17, reflecting an increase of around 100%[198]. - The company reported a significant increase in accounts payable, rising to ¥110,735,822.36 from ¥76,919,527.44, which is an increase of about 44%[198].

Financial Performance - In Q1 2023, the company reported a net profit of ¥18,885,415.84, an increase from ¥14,993,326.89 in Q1 2022, representing a growth of approximately 25.6%[12] - Basic earnings per share for Q1 2023 was reported at ¥0.10, up from ¥0.08 in Q1 2022, indicating a growth of 25%[12] - The company’s operating profit for the quarter was ¥23,528,055.19, compared to ¥14,930,312.73 in the same period last year, reflecting a significant increase of about 57.5%[12] - The net profit attributable to shareholders of the listed company for Q1 2023 was RMB 21,012,921.56, reflecting a 30.56% year-on-year growth[30] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 23,382,586.67, which is an increase of 84.35% year-on-year[30] - The net profit after deducting non-recurring gains and losses surged by 84.35% due to increased sales revenue[42] Assets and Liabilities - The total assets as of March 31, 2023, amounted to ¥2,592,700,235.07, compared to ¥2,522,299,186.67 at the end of 2022, indicating an increase of about 2.8%[10] - The total liabilities rose to ¥648,695,474.24 from ¥597,412,479.77, marking an increase of about 8.6%[10] - The total equity attributable to shareholders increased to ¥1,931,471,658.69 from ¥1,910,226,099.04, representing a growth of approximately 1.1%[10] - The total non-current assets reached RMB 1,502,113,796.17, compared to RMB 1,469,829,602.50 in the previous year[36] - The total liabilities for the company were RMB 604,120,687.19, an increase from RMB 551,323,149.93 in the previous year[36] Cash Flow - The company's cash and cash equivalents increased to ¥478,034,709.32 from ¥399,964,705.79 year-over-year, reflecting a growth of approximately 19.5%[9] - The net cash flow from operating activities for Q1 2023 was RMB 144,720,177.89, showing a significant increase of 9,897.52% compared to the previous year[30] - Cash flow from operating activities amounted to CNY 144,720,177.89, significantly up from CNY 1,447,560.62 in the previous period[50] - Net cash inflow from operating activities was CNY 308,976,823.93, compared to CNY 144,960,960.65 in the previous year[50] - The net increase in cash and cash equivalents was $94,551,033.29, contrasting with a decrease of $37,593,550.63 in the previous year[61] Revenue and Expenses - The company's total operating revenue for Q1 2023 was RMB 208,058,681.69, representing a 54.98% increase compared to the same period last year[30] - Operating revenue for the period was CNY 208,058,681.69, a 54.98% increase year-on-year[48] - Research and development expenses totaled CNY 20,884,102.29, representing a 59.59% increase[42] - Research and development expenses accounted for 10.04% of operating revenue, up 0.29 percentage points[41] Shareholder Information - The company has a total of 10,609 shareholders at the end of the reporting period[32] - The weighted average return on equity rose to 1.09%, an increase of 0.21 percentage points[41] Other Financial Activities - The company reported a loss of RMB 5,502,004.42 from the disposal of a waste warehouse during the reporting period[30] - The company received government subsidies amounting to RMB 2,731,880.44, which are closely related to its normal business operations[30] - The company has no reported financing or margin trading activities among its top shareholders[7] - There were no mergers or acquisitions reported during the period, with no net profit from merged entities[13] - Cash inflow from investment activities totaled $106,461,541.49, down from $212,512,573.97 year-over-year[61] - Cash outflow for investment activities was $252,391,749.91, compared to $315,912,070.61 in the previous period[61] - Net cash flow from investment activities was -$145,930,208.42, worsening from -$103,399,496.64 year-over-year[61] - Cash inflow from financing activities increased to $155,000,000.00, up from $82,700,000.00 in the previous period[61] - Cash outflow for financing activities was $59,236,521.22, compared to $18,190,587.09 last year[61] - Net cash flow from financing activities improved to $95,763,478.78, compared to $64,509,412.91 in the previous period[61]

Financial Performance - Revenue for Q3 2022 was ¥113,938,273.65, a decrease of 19.12% compared to the same period last year[8] - Net profit attributable to shareholders for Q3 2022 was ¥18,361,297.20, down 16.02% year-over-year[8] - Net profit excluding non-recurring gains and losses for Q3 2022 was ¥578,020.36, a significant decline of 96.85% compared to the same period last year[8] - Total operating revenue for the first three quarters of 2022 was ¥382,238,680.01, a decrease of 15% compared to ¥449,877,162.41 in the same period of 2021[32] - Net profit for the third quarter of 2022 was ¥48,653,233.84, down 30% from ¥69,525,337.97 in the third quarter of 2021[38] - Earnings per share for the third quarter of 2022 were ¥0.25, compared to ¥0.40 in the same quarter of 2021[40] Research and Development - R&D investment for Q3 2022 totaled ¥20,523,354.60, an increase of 49.04% year-over-year, representing 18.01% of revenue[12] - Research and development expenses for the third quarter of 2022 were ¥49,547,134.58, an increase from ¥44,422,127.37 in the previous year[35] Assets and Liabilities - Total assets at the end of Q3 2022 were ¥2,376,710,654.67, an increase of 11.74% from the end of the previous year[12] - The company's total assets amounted to approximately ¥2.38 billion, an increase from ¥2.13 billion at the end of 2021, reflecting a growth of about 11.7%[30] - The company's total liabilities increased to ¥526,122,650.75 in 2022 from ¥318,137,446.34 in 2021[32] - Total current liabilities rose to approximately ¥483.28 million, up from ¥275.40 million, reflecting an increase of about 75.4% year-over-year[30] - The company's non-current assets totaled approximately ¥1.36 billion, an increase from ¥1.02 billion, indicating a growth of about 33.1%[30] Cash Flow - Cash flow from operating activities for the year-to-date was negative at -¥15,425,321.93, a decline of 111.70% compared to the previous year[12] - The net cash flow from operating activities was -$15,425,321.93, a significant decrease compared to $131,827,280.03 in the previous period[42] - Cash inflow from operating activities for the first three quarters of 2022 was ¥409,786,781.52, down from ¥554,516,533.82 in the same period of 2021[41] - The cash outflow for operating activities was $425,212,103.45, slightly higher than $422,689,253.79 in the previous period[42] Investments and Financing - The company reported a significant increase in investment income to ¥19,813,526.18 in the third quarter of 2022, compared to ¥1,790,339.17 in the same quarter of 2021[35] - Cash inflow from investment activities totaled $633,880,182.43, slightly down from $638,790,339.17 year-over-year[42] - The net cash flow from investment activities was -$349,190,220.68, worsening from -$202,083,694.94 in the prior period[42] - Cash inflow from financing activities was $372,140,000.00, a decrease from $884,930,398.14 in the previous year[42] - The net cash flow from financing activities was $218,839,953.16, down from $521,003,577.78 year-over-year[42] Other Notable Points - The company reported an increase in management and sales expenses, contributing to the decline in net profit[17] - The company's cash and cash equivalents decreased to approximately ¥428.81 million from ¥591.88 million, representing a decline of about 27.5% year-over-year[27] - Inventory levels increased significantly to approximately ¥330.17 million, up from ¥250.82 million, indicating a rise of approximately 31.7% compared to the previous year[27] - The company's short-term borrowings surged to approximately ¥298.36 million, compared to ¥77.27 million at the end of 2021, marking an increase of about 286.5%[30] - The company has no significant updates regarding new products or technologies in the current report period[24] - There are no notable mergers or acquisitions reported during the current period[24] - The company has not provided specific future guidance or outlook in the current report[24]

Financial Performance - The company reported a total revenue of RMB 200 million for the first half of 2022, representing a 15% increase compared to the same period in 2021[19]. - The net profit for the first half of 2022 was RMB 50 million, which is a 10% increase year-over-year[19]. - The company's operating revenue for the first half of the year was ¥268,300,406.36, a decrease of 13.17% compared to ¥309,003,487.50 in the same period last year[26]. - The net profit attributable to shareholders decreased by 32.25% to ¥34,833,587.68 from ¥51,417,973.86 year-on-year[26]. - The net profit after deducting non-recurring gains and losses fell by 75.57% to ¥11,433,014.46, primarily due to a decline in net profit and investment income from the disposal of equity[26]. - The net cash flow from operating activities was negative at -¥14,608,397.00, a decrease of 116.87% compared to ¥86,589,089.55 in the previous year[26]. - Basic earnings per share decreased by 46.67% to ¥0.16 from ¥0.30 year-on-year[27]. - The company has set a revenue guidance of RMB 500 million for the full year 2022, indicating a growth target of 25% compared to 2021[19]. Research and Development - Research and development expenses increased by 20% to RMB 30 million, reflecting the company's commitment to innovation and new technology[19]. - The R&D investment as a percentage of operating revenue increased by 2.61 percentage points to 13.35%[30]. - The company has 195 R&D personnel, representing 17.74% of total employees, an increase from 170 personnel in the previous year[71]. - Total R&D personnel compensation increased to ¥1,965.46 million, with average compensation rising to ¥10.08 million[71]. - The company reported a 7.42% increase in capitalized R&D expenses, totaling ¥33,462,572.05 compared to ¥31,150,413.61 in the same period last year[63]. - The company’s R&D investment as a percentage of operating revenue is among the highest in the industry at 13.35%[75]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a revenue growth of 30% in that region by the end of 2023[19]. - A strategic acquisition of a local biotech firm is expected to be finalized by Q1 2023, which will enhance the company's product portfolio[19]. - The company plans to launch two new products in Q4 2022, aiming to capture an additional 5% market share in the biopharmaceutical sector[19]. - The company is focusing on the development of peptide drugs and small molecule drugs, with a shift towards customized products and technical services as the main revenue source[35]. Environmental and Safety Compliance - The company is listed as a key pollutant discharge unit in Lianyungang City, with its subsidiary Aosaino also listed in Hangzhou[126]. - Major pollutants generated during production include COD, SS, ammonia nitrogen, and non-methane total hydrocarbons, with effective treatment measures in place[126]. - The company has established dedicated EHS departments at production bases to manage environmental and occupational health safety[126]. - The company has invested significantly in optimizing production processes to reduce environmental impact[126]. - The company has implemented a comprehensive EHS management system to control significant environmental impact factors[126]. - The company has achieved compliance with environmental standards for wastewater and waste gas emissions through effective treatment processes[140]. Corporate Governance and Shareholder Commitments - The company has committed to a share lock-up period of 36 months starting from May 20, 2021, for major shareholders and related parties, ensuring compliance with the commitment[153]. - The company has established a mechanism to resolve related party transactions and competition issues, maintaining transparency and compliance[156]. - The company has outlined strict regulations for share reduction by its executives, limiting annual transfers to 25% of their holdings during their tenure and 6 months post-termination[158]. - The company has committed to adhering to all relevant regulations regarding share transfers and reductions as stipulated by the China Securities Regulatory Commission and the Shanghai Stock Exchange[158]. - The company will notify and announce any intended share reductions 3 trading days prior to execution after the lock-up period[160].

Financial Performance - The company's revenue for Q3 2021 was ¥140,873,674.91, representing a decrease of 11.09% compared to the same period last year[6]. - The net profit attributable to shareholders for Q3 2021 was ¥21,864,514.31, down 38.42% year-over-year[6]. - The net profit after deducting non-recurring gains and losses for Q3 2021 was ¥18,359,658.26, a decrease of 30.80% compared to the previous year[9]. - Net profit for the third quarter of 2021 was ¥69,525,337.97, compared to ¥78,888,059.93 in the third quarter of 2020, indicating a decrease of about 11.5%[37]. - Basic earnings per share for Q3 2021 were ¥0.10, down 54.55% year-over-year[9]. - The basic earnings per share for the third quarter of 2021 was ¥0.40, down from ¥0.52 in the same quarter of 2020, reflecting a decrease of approximately 23.1%[40]. - The company's return on assets (ROA) for Q3 2021 was 1.25%, a decrease of 2.68 percentage points compared to the previous year[9]. Assets and Equity - The total assets at the end of the reporting period were ¥2,026,842,599.47, an increase of 45.23% compared to the end of the previous year[9]. - The equity attributable to shareholders at the end of the reporting period was ¥1,767,847,999.98, up 83.51% year-over-year[9]. - The total current assets have increased to ¥1,028,831,337.92 from ¥487,908,101.27 year-over-year[30]. - The total assets of the company as of September 30, 2021, are ¥2,026,842,599.47, compared to ¥1,395,573,459.13 at the end of 2020[30]. - The total non-current assets have increased to ¥998,011,261.55 from ¥907,665,357.86 year-over-year[30]. - The total equity attributable to shareholders reached ¥1,767,847,999.98, significantly increasing from ¥963,343,985.32 in the previous year, marking a growth of approximately 83.6%[35]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥131,827,280.03, an increase of 32.04% compared to the previous year[9]. - Operating cash inflow for the first three quarters of 2021 was RMB 554,516,533.82, an increase of 32.5% compared to RMB 418,439,683.58 in the same period of 2020[45]. - Net cash flow from operating activities for the first three quarters of 2021 was RMB 131,827,280.03, up from RMB 99,840,845.29 in 2020, representing a growth of 32.1%[45]. - The ending balance of cash and cash equivalents as of the end of the reporting period was RMB 518,246,380.64, compared to RMB 72,935,999.09 at the end of the previous year[47]. - The company reported a cash inflow of RMB 762,629,380.06 from new investments in 2021, reflecting strong investor confidence[47]. Expenses - Research and development expenses for Q3 2021 totaled ¥13,769,947.43, a decrease of 38.41% compared to the same period last year[9]. - Research and development expenses for the first three quarters of 2021 amounted to ¥44,422,127.37, slightly up from ¥43,349,679.30 in the same period of 2020, reflecting a growth of approximately 2.5%[36]. - The company's total operating costs for the first three quarters of 2021 were ¥362,873,515.63, compared to ¥304,705,301.11 in the same period of 2020, which is an increase of about 19.1%[36]. - The company experienced an increase in management and sales expenses, contributing to the decline in net profit[16]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 12,846[19]. - The largest shareholder, Lianyungang Nuotai Investment Management Partnership, holds 20,000,000 shares, accounting for 9.38% of the total shares[19]. - The second and third largest shareholders, Zhao Deyi and Zhao Dezhong, each hold 13,414,000 shares, representing 6.29% of the total shares[19]. - The company has no pledged, marked, or frozen shares among the top shareholders[19]. - The company has not disclosed any significant related party transactions or agreements among shareholders beyond the known relationships[26]. Liabilities - The total liabilities of the company as of the latest report were ¥259,019,473.73, down from ¥429,548,577.85 in the previous period, showing a reduction of about 39.8%[33]. - The total non-current liabilities were reported at ¥44,809,096.01, a slight decrease from ¥47,338,215.16 in the previous period, showing a reduction of approximately 5.3%[33].

Financial Performance - The company achieved operating revenue of CNY 643.87 million, an increase of 13.58% compared to 2020[29]. - The net profit attributable to shareholders in 2021 was CNY 115.39 million, a decrease of 6.52% year-on-year[33]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 104.83 million, an increase of 10.96% compared to the previous year[33]. - The net cash flow from operating activities increased by 27.84% year-on-year, primarily due to higher customer payments received[33]. - The company's total assets at the end of 2021 grew by 52.40% compared to the beginning of the year, mainly due to funds raised from the initial public offering[33]. - The net assets attributable to shareholders increased by 88.03% at the end of 2021 compared to the beginning of the year[33]. - Basic earnings per share in 2021 decreased by 22.08% to CNY 0.60, primarily due to an increase in the number of shares outstanding[34]. - The company reported a total R&D investment of ¥68,762,650.90, a 2.50% increase from the previous year, with a ratio of R&D investment to operating income at 10.68%[130]. - The company experienced a significant decrease in financial expenses by 86.93%, amounting to 2.56 million RMB[158]. - The company’s retained earnings increased by 66.23% to 266,300,074.09 RMB, reflecting a rise in net profit[187]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 1.50 per 10 shares, totaling RMB 31,977,570.00 based on a total share capital of 213,183,800 shares as of March 31, 2022[7]. - The company has not proposed any bonus shares or capital reserve transfers to increase share capital for the 2021 fiscal year[7]. Corporate Governance and Compliance - The board of directors has confirmed the accuracy and completeness of the annual report, ensuring no significant omissions or misleading statements[4]. - The company has received a standard unqualified audit report from Zhongtian Accounting Firm[6]. - There are no non-operational fund occupations by controlling shareholders or related parties reported[11]. - The company has not violated decision-making procedures for external guarantees[11]. - The company does not have any special arrangements for corporate governance[11]. Research and Development - The company invested CNY 68.76 million in R&D, representing 10.68% of its revenue, and completed 25 new project developments, with 17 projects achieving factory-scale production[56]. - The company has filed 20 invention patents and obtained 12 during the reporting period, bringing the cumulative total to 129 applications and 46 grants[129]. - The company has 183 R&D personnel, accounting for 16.77% of the total workforce, with an average salary of 17.89 million RMB[136]. - The company is currently working on 12 projects, with several in the registration and stability research phases, aiming for product approvals and market entry[136]. - The company is focusing on GLP-1 receptor agonists for diabetes treatment, with several innovative drugs already on the market generating significant sales[122]. Market and Industry Trends - The global pharmaceutical market is projected to exceed $1.5 trillion by 2023, with a CAGR of 3%-6% from 2019 to 2023[86]. - China's pharmaceutical spending is expected to reach $140-170 billion by 2023, with a CAGR of 3%-6%[88]. - The global small molecule CDMO/CMO market is anticipated to grow from $64.6 billion in 2018 to $107.2 billion by 2023, with a CAGR of 10.7%[92]. - The peptide drug market in China is projected to grow from $8.5 billion in 2020 to $18.2 billion by 2025, with a CAGR of 16.3%[93]. Operational Strategies - The company has focused on maintaining existing customers and developing new clients, which contributed to revenue growth[33]. - The company plans to enhance resource allocation in the CDMO business to improve overall competitiveness, including expanding the BD team in the US and Europe[51]. - The company has adopted video conferencing and cloud audits to effectively develop new customers during the pandemic[52]. - The company’s sales strategy includes direct sales to well-known innovative pharmaceutical companies and leveraging distributors for market expansion in overseas markets[82]. Risks and Challenges - The company has outlined potential risks in its operations, which are detailed in the report's risk factors section[5]. - The company faces risks related to core competitiveness due to the high technical difficulty and long development cycles in drug R&D[145]. - The company is exposed to financial risks from foreign exchange fluctuations, as a significant portion of revenue comes from overseas and is priced in foreign currencies[149]. - The competitive landscape in the custom product development sector is intensifying, requiring the company to enhance its market development capabilities[150]. - The company is subject to regulatory risks in the pharmaceutical industry, which could impact its operational strategies and profitability[151]. Production and Capacity - The company has initiated the construction of a second-phase GMP production workshop, expected to add approximately 400,000 liters of capacity, to be gradually delivered in 2022 and 2023[51]. - The production capacity of the APC180 project at the Lianyungang factory has been expanded to 2.5 times the original capacity, ensuring effective support for new orders[51]. - The company has established two modern production bases in Jiande and Lianyungang, with a total capacity of 107.50 million liters, and is expanding capacity by an additional 40 million liters[140]. Customer and Market Development - Direct sales accounted for 85.96% of the company's business, with 5 new end customers developed in Europe and the US for its self-developed raw materials[55]. - The company has established solid relationships with major pharmaceutical clients, including Incyte and Gilead, which enhances customer retention and business opportunities[144]. - The company has developed five new domestic customers and increased CDMO R&D personnel by 13, including one returning PhD and one postdoctoral researcher[51]. Product Pipeline and Innovations - The company has developed a robust pipeline of peptide APIs, including seven key products that have already been commercialized, contributing to revenue and profit[67]. - The company has completed the registration and submission of various raw materials and formulations, including the successful registration of the injection of exenatide[57]. - The company has designed and screened multiple compounds with dual agonist activity for GIP and GLP-1, which are expected to have favorable pharmacokinetic properties[124]. - The company has made significant progress in the development of peptide-targeted anti-tumor drugs, focusing on reducing side effects and improving drug delivery to tumor sites[126].